The efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia: a meta-analysis of randomized controlled studies

Abstract

Introduction

The efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia remains controversial. We conduct a systematic review and meta-analysis to explore the influence of intravenous fluid supplementation on treatment efficacy of neonatal hyperbilirubinemia.

Methods

We search PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases through June 2019 for randomized controlled trials (RCTs) assessing the efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia. This meta-analysis is performed using the random-effect model.

Results

Six RCTs are included in the meta-analysis. Overall, compared with control group for neonatal hyperbilirubinemia, intravenous fluid supplementation is associated with decreased TSB at 8 h (std. MD = −0.82; 95% CI = −1.46 to −0.17; p = .01), 12 h (std. MD = −0.46; 95% CI = −0.81 to −0.10; p = .01), 24 h (std. MD = −0.47; 95% CI = −0.78 to −0.16; p = .003) and 36 h (std. MD = −0.37; 95% CI = −0.73 to −0.02; p = .04), as well as reduced incidence of exchange transfusion (RR = 0.29; 95% CI = 0.14–0.59; p = .0006), but has no significant impact on duration of phototherapy (std. MD = −0.34; 95% CI = −0.88–0.21; p = .22).

Conclusions

Intravenous fluid supplementation can provide additional benefits for the treatment of neonatal hyperbilirubinemia.

Keywords:

• Fluid supplementation
• neonatal hyperbilirubinemia
• randomized controlled trials
• treatment efficacy

Disclosure statement

No potential conflict of interest was reported by the authors.